Drug development is a risky endeavor, especially for a startup company. It requires large capital expenditures, waiting out long timelines and overcoming regulatory hurdles to bring a drug to market. Prioritizing and valuing which drugs to develop can make or break a company.

That’s why the Pennsylvania-based biopharmaceutical startup, SFA Therapeutics, brought in Josh Lankin […]